NEW YORK, Aug. 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=162488&from=4CLASS PERIOD: April 29, ...

CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over- the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleadin ...

Core Viewpoint - Hims & Hers is facing a securities class action lawsuit due to allegations of misleading statements regarding its GLP-1 weight-loss drug business and a partnership with Novo Nordisk that was abruptly terminated [1][4][5] Group 1: Lawsuit Details - The class action lawsuit represents investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, alleging violations of the Securities Exchange Act of 1934 [3] - The lawsuit claims that Hims & Hers and its executives made false and misleading statements to investors, particularly concerning the partnership with Novo Nordisk [3][4] - The deadline for investors to apply as Lead Plaintiff is August 25, 2025 [2][3] Group 2: Allegations of Misconduct - The core allegations involve Hims & Hers' deceptive promotion and sale of "illegitimate, knockoff versions of Wegovy®," which allegedly jeopardized patient safety and led to the termination of the partnership with Novo Nordisk [4][5] - Novo Nordisk cited Hims & Hers' "deceptive promotion and selling" as the reason for ending the collaboration, which resulted in a stock price drop of over 34% on June 23, 2025 [2][5] Group 3: Investigations and Implications - The Federal Trade Commission (FTC) is investigating Hims & Hers over its advertising and subscription cancellation practices [6] - Hagens Berman is investigating whether Hims & Hers misled investors about its business practices, particularly regarding compounded weight-loss drugs and the terminated partnership [7][8] - The swift termination of the Novo Nordisk deal and the subsequent stock price collapse suggest a potential disconnect between what investors were told and the actual operations of Hims & Hers [8]

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating Hims & Hers for possible violations of federal securities laws during the Class Period from April 29, 2025, to June 22, 2025 [1]. - The investigation follows a significant drop in Hims & Hers' stock price, which fell over 34% after Novo Nordisk terminated its partnership due to unauthorized marketing and sale of compounded semaglutide drugs [2]. - A complaint has been filed alleging that Hims & Hers made material misstatements and omissions, violating federal securities laws [2]. Group 2: Legal Actions - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other affected investors [3].

SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as c ...

Core Viewpoint - Hims & Hers (NYSE: HIMS) is considered one of the most undervalued growth stories in the telehealth sector, with a reported Q2 revenue of $545 million, reflecting a 73% year-over-year increase, positioning the company for an annual revenue of $2.4 billion [1] Company Summary - Hims & Hers reported Q2 revenue of $545 million, which is a 73% increase compared to the previous year [1] - The company is on track to achieve an annual revenue of $2.4 billion [1] Industry Context - The telehealth industry is experiencing significant growth, with companies like Hims & Hers leading the way in terms of revenue increases and market potential [1]

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a substantial risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Investor Actions - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and selects counsel to represent the class in litigation [3]. - Investors can choose to remain absent from the class action without affecting their ability to share in any recovery [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Insights - Hims & Hers Health, Inc. (HIMS) is focused on democratizing access to personalized healthcare, particularly in underserved areas, with a subscriber base of 2.4 million and nearly 1,500 licensed providers by Q2 2025 [1][7] - The company is expanding into hormonal health, targeting menopause and low testosterone, which presents a significant market opportunity in the U.S. [2][7] - International expansion through the acquisition of ZAVA enhances Hims & Hers' presence in Europe, gaining access to over 1.3 million patients, with plans to enter Canada in 2026 [3][7] Market Performance - Hims & Hers shares have increased by 86.5% year-to-date, outperforming the industry growth of 23.5% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 3.8X, lower than the industry average of 5.8X but higher than its three-year median of 2.4X [8] Financial Estimates - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 indicates a 137% improvement from 2024 [9] - Current consensus estimates for HIMS' earnings per share are 0.12 for Q3 2025, 0.14 for Q4 2025, 0.64 for the current year, and 0.89 for the next year [12]

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Hims & Hers Health, Inc. engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - It is alleged that this misconduct posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis due to the aforementioned issues [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].